Skip to main content

Advertisement

Log in

The association between cancer and amyotrophic lateral sclerosis

Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Objective

Increasing evidence suggests that some neurodegenerative disorders, such as Parkinson’s disease, are inversely related to cancer. Few epidemiologic studies have examined the relationship between cancer and amyotrophic lateral sclerosis (ALS), another major neurodegenerative disease. This study addresses that gap.

Methods

Using data from 16 population-based cancer registries of the Surveillance, Epidemiology, and End Results (SEER) Program of the U.S. National Cancer Institute and death certificates, we followed 2.7 million cancer survivors who were diagnosed between 1973 and 2007, and who survived at least 1 year following cancer diagnosis. The standardized mortality ratio (SMR) of observed to expected ALS deaths in cancer survivors was calculated.

Results

A total of 1,216 ALS deaths were reported among 1 year survivors of cancer over 16.6 million person-years of follow-up. ALS mortality was not significantly associated with the incidence of total cancers [SMR = 1.00 (95 % confidence interval (CI), 0.95–1.06)]. There was, however, a significantly elevated risk of ALS death among survivors of melanoma [SMR = 1.49 (95 % (CI), 1.17–1.85)] and of tongue cancer [SMR = 2.57 (95 % CI, 1.41–4.32)], and a significantly reduced ALS death risk among prostate cancer survivors [SMR = 0.86 (95 % CI, 0.76–0.96)].

Conclusions

Cancer at certain sites may be related to risk of ALS death. Possible biologic factors linking ALS to these cancers are discussed. Future studies should attempt to confirm these associations using incident ALS outcomes. Establishing relationships between cancer and neurodegenerative diseases, such as ALS, opens new opportunities for understanding related pathophysiologic and therapeutic possibilities for these diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Plun-Favreau H, Lewis PA, Hardy J, Martins LM, Wood NW (2010) Cancer and neurodegeneration: between the devil and the deep blue sea. PLoS Genet 6:e1001257

    Article  PubMed  CAS  Google Scholar 

  2. Tabares-Seisdedos R, Dumont N, Baudot A et al (2011) No paradox, no progress: inverse cancer comorbidity in people with other complex diseases. Lancet Oncol 12:604–608

    Article  PubMed  Google Scholar 

  3. Devine MJ, Plun-Favreau H, Wood NW (2011) Parkinson’s disease and cancer: two wars, one front. Nat Rev Cancer 11:812–823

    Google Scholar 

  4. Roe CM, Fitzpatrick AL, Xiong C et al (2010) Cancer linked to Alzheimer disease but not vascular dementia. Neurology 74:106–112

    Article  PubMed  CAS  Google Scholar 

  5. Bajaj A, Driver JA, Schernhammer ES (2010) Parkinson’s disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 21:697–707

    Article  PubMed  Google Scholar 

  6. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H (2005) Atypical cancer pattern in patients with Parkinson’s disease. Br J Cancer 92:201–205

    Article  PubMed  CAS  Google Scholar 

  7. Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T (2007) A prospective cohort study of cancer incidence following the diagnosis of Parkinson’s disease. Cancer Epidemiol Biomarkers Prev 16:1260–1265

    Article  PubMed  Google Scholar 

  8. Driver JA, Beiser A, Au R et al (2012) Inverse association between cancer and Alzheimer’s disease: results from the Framingham Heart Study. BMJ 344:e1442

    Article  PubMed  Google Scholar 

  9. Olsen JH, Friis S, Frederiksen K (2006) Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 17:582–587

    Article  PubMed  Google Scholar 

  10. Freedman DM, Travis LB, Gridley G, Kuncl RW (2005) Amyotrophic lateral sclerosis mortality in 1.9 million US cancer survivors. Neuroepidemiology 25:176–180

    Article  PubMed  Google Scholar 

  11. Baade PD, Fritschi L, Freedman DM (2007) Mortality due to amyotrophic lateral sclerosis and Parkinson’s disease among melanoma patients. Neuroepidemiology 28:16–20

    Article  PubMed  CAS  Google Scholar 

  12. Zisfein J, Caroscio JT (1988) No association of amyotrophic lateral sclerosis with cancer. Mt Sinai J Med 55:159–161

    PubMed  CAS  Google Scholar 

  13. Chio A, Brignolio F, Meineri P, Rosso MG, Tribolo A, Schiffer D (1988) Motor neuron disease and malignancies: results of a population-based study. J Neurol 235:374–375

    Article  PubMed  CAS  Google Scholar 

  14. Kurtzke JF, Beebe GW (1980) Epidemiology of amyotrophic lateral sclerosis: 1. A case–control comparison based on ALS deaths. Neurology 30:453–462

    Article  PubMed  CAS  Google Scholar 

  15. Kondo K (1984) Motor neuron disease and Parkinson’s disease are not associated with other disorders at autopsy. Neuroepidemiology 3:182–194

    Article  Google Scholar 

  16. Rowland LP, Shneider NA (2001) Amyotrophic lateral sclerosis. N Engl J Med 344:1688–1700

    Article  PubMed  CAS  Google Scholar 

  17. Kiernan MC, Vucic S, Cheah BC et al (2011) Amyotrophic lateral sclerosis. Lancet 377:942–955

    Article  PubMed  CAS  Google Scholar 

  18. Logroscino G, Traynor BJ, Hardiman O et al (2008) Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry 79:6–11

    Article  PubMed  CAS  Google Scholar 

  19. Steenland K, MacNeil J, Seals R, Levey A (2010) Factors affecting survival of patients with neurodegenerative disease. Neuroepidemiology 35:28–35

    Article  PubMed  Google Scholar 

  20. Mateen FJ, Carone M, Sorenson EJ (2010) Patients who survive 5 years or more with ALS in Olmsted County, 1925–2004. J Neurol Neurosurg Psychiatry 81:1144–1146

    Article  PubMed  Google Scholar 

  21. Chio A, Logroscino G, Hardiman O et al (2009) Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 10:310–323

    Article  PubMed  Google Scholar 

  22. Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr (2006) New malignancies among cancer survivors: SEER cancer registries, 1973–2000. National Cancer Institute, Bethesda

    Google Scholar 

  23. Swan J, Wingo P, Clive R et al (1998) Cancer surveillance in the U.S.: can we have a national system? Cancer 83:1282–1291

    Article  PubMed  CAS  Google Scholar 

  24. Leone M, Chandra V, Schoenberg BS (1987) Motor neuron disease in the United States, 1971 and 1973–1978: patterns of mortality and associated conditions at the time of death. Neurology 37:1339–1343

    Article  PubMed  CAS  Google Scholar 

  25. Barry MJ (2001) Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 344:1373–1377

    Article  PubMed  CAS  Google Scholar 

  26. Baade PD, Herrero Hernandez E, Freedman DM, Smithers BM, Fritschi L (2010) No role for melanoma treatment in the association between melanoma and amyotrophic lateral sclerosis or Parkinson’s disease. Neuroepidemiology 35:303–304

    Article  PubMed  Google Scholar 

  27. Habib AA, Mitsumoto H (2011) Emerging drugs for amyotrophic lateral sclerosis. Expert Opin Emerg Drugs 16:537–558

    Article  PubMed  Google Scholar 

  28. Lee HJ, Wall BA, Wangari-Talbot J et al (2011) Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. Clin Cancer Res 17:7080–7092

    Article  PubMed  CAS  Google Scholar 

  29. Stepulak A, Luksch H, Gebhardt C et al (2009) Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol 132:435–445

    Article  PubMed  CAS  Google Scholar 

  30. Speyer CL, Smith JS, Banda M, Devries JA, Mekani T, Gorski DH (2012) Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. Breast Cancer Res Treat 132:565–573

    Google Scholar 

  31. Yip D, Le MN, Chan JL et al (2009) A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin Cancer Res 15:3896–3902

    Article  PubMed  CAS  Google Scholar 

  32. Cavalheiro EA, Olney JW (2001) Glutamate antagonists: deadly liaisons with cancer. Proc Natl Acad Sci USA 98:5947–5948

    Article  PubMed  CAS  Google Scholar 

  33. Yasui K, Oketa Y, Higashida K, Fukazawa H, Ono S (2011) Increased progranulin in the skin of amyotrophic lateral sclerosis: an immunohistochemical study. J Neurol Sci 309:110–114

    Article  PubMed  CAS  Google Scholar 

  34. Watanabe T, Okeda Y, Yamano T, Ono S (2010) An immunohistochemical study of ubiquitin in the skin of sporadic amyotrophic lateral sclerosis. J Neurol Sci 298:52–56

    Article  PubMed  CAS  Google Scholar 

  35. Suzuki M, Mikami H, Watanabe T et al (2010) Increased expression of TDP-43 in the skin of amyotrophic lateral sclerosis. Acta Neurol Scand 122:367–372

    Article  PubMed  CAS  Google Scholar 

  36. Nomura M, Oketa Y, Yasui K, Ishikawa H, Ono S (2012) Expression of hepatocyte growth factor in the skin of amyotrophic lateral sclerosis. Acta Neurol Scand 125:389–397

    Google Scholar 

  37. Bogenrieder T, Herlyn M (2010) The molecular pathology of cutaneous melanoma. Cancer Biomark 9:267–286

    PubMed  Google Scholar 

  38. Park SY, Lee SA, Han IH et al (2007) Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma. Oncol Rep 17:81–87

    PubMed  Google Scholar 

  39. Kasper JS, Liu Y, Giovannucci E (2009) Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 124:1398–1403

    Article  PubMed  CAS  Google Scholar 

  40. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM (2009) Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124:2416–2429

    Article  PubMed  CAS  Google Scholar 

  41. Sakowski SA, Schuyler AD, Feldman EL (2009) Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 10:63–73

    Article  PubMed  CAS  Google Scholar 

  42. Sorenson EJ, Windbank AJ, Mandrekar JN et al (2008) Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 71:1770–1775

    Article  PubMed  CAS  Google Scholar 

  43. Bilak MM, Kuncl RW (2001) Delayed application of IGF-I and GDNF can rescue already injured postnatal motor neurons. NeuroReport 12:2531–2535

    Article  PubMed  CAS  Google Scholar 

  44. Marin B, Couratier P, Preux PM, Logroscino G (2011) Can mortality data be used to estimate amyotrophic lateral sclerosis incidence? Neuroepidemiology 36:29–38

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This research was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, and the U.S. Public Health Service of the Department of Health and Human Services. We thank Jeremy Miller of Information Management Services, Inc. for biomedical computer assistance and Dr. Robert J. Biggar of Queensland University of Technology for his helpful comments.

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D. Michal Freedman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Freedman, D.M., Curtis, R.E., Daugherty, S.E. et al. The association between cancer and amyotrophic lateral sclerosis. Cancer Causes Control 24, 55–60 (2013). https://doi.org/10.1007/s10552-012-0089-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-012-0089-5

Keywords

Navigation